Welcome to our dedicated page for Precision BioSciences news (Ticker: $DTIL), a resource for investors and traders seeking the latest updates and insights on Precision BioSciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Precision BioSciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Precision BioSciences's position in the market.
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announces a 1-for-30 reverse stock split to increase per share market price and meet Nasdaq listing requirements. The split will be effective on February 13, 2024, with trading under the existing symbol 'DTIL'. Shareholders will receive one new share for every 30 shares held.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) has completed a strategic transaction with TG Therapeutics, Inc. to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases. Precision will receive $17.5 million upfront and near-term payments, with potential for up to $288 million in other development milestone payments. The upfront cash and near-term payments are expected to extend Precision’s cash runway into the first half of 2026 and fund Precision’s Wholly-Owned In Vivo Gene Editing Programs through PBGENE-HBV and PBGENE-PMM Phase I Clinical Data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.1%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) partner iECURE receives clearance from Australian Therapeutic Goods Administration for Phase 1/2 study of ECUR-506 for the treatment of Ornithine Transcarbamylase (OTC) deficiency. The approval marks a significant milestone for patients and the company, with promising preclinical results indicating the potential for a curative treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
Rhea-AI Summary
iECURE, Inc. (ECUR) announced that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Clinical Trial Notification (CTN) for ECUR-506, an investigational therapy for the treatment of Ornithine Transcarbamylase (OTC) deficiency in pediatric patients. The CTN approval represents the first of such regulatory approvals to begin clinical trials, with additional approvals expected in 2024. The company is in the process of preparing sites for the global, first-in-human Phase 1/2 clinical study and anticipates initiation of such clinical trial in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announced the publication in Nature Metabolism of a peer-reviewed manuscript supporting the development of the PBGENE-PMM in vivo gene editing program as a potentially curative therapeutic approach for patients with m.3243-associated primary mitochondrial myopathy. The publication validates the unique ability of ARCUS genome editing to target and eliminate mutant m.3243G mitochondrial DNA with high specificity, leading to an overall improvement in mitochondrial function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) will present at Hep-DART 2023 in Los Cabos, Mexico, showcasing their PBGENE-HBV Program for gene editing therapies to potentially cure chronic hepatitis B. Presenters include Jeff Smith, Co-Founder and Chief Research Officer, and Emily Harrison, HBV Research Lead.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announced the approval of an inducement award for a new employee under the 2021 Employment Inducement Incentive Award Plan. The award consists of a stock option to purchase 160,000 shares of Precision's common stock at an exercise price of $0.42 per share, with a 10-year term and vesting over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.53%
Tags
-
Rhea-AI Summary
DTIL - Precision BioSciences, Inc. presents late-breaking data at AASLD's The Liver Meeting on PBGENE-HBV, demonstrating up to 99% viral engagement and final clinical candidate readiness for CTA and/or IND filing in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.5%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) to Present at Sidoti November Micro Cap Conference on November 15, 2023. The company will showcase its gene editing therapies utilizing the ARCUS® platform. The presentation details are available on Precision’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) announced that an abstract featuring preclinical data for its PBGENE-HBV program has been accepted for late-breaker presentation at the American Association for the Study of Liver Diseases Annual Meeting. The company will host a webcast and conference call on November 13, 2023, to discuss program updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
Precision BioSciences, Inc.
Nasdaq:DTIL
DTIL Rankings
DTIL Stock Data
85.88M
5.24M
8.48%
39.81%
4.18%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
DURHAM
About DTIL
precision biosciences, inc. is a biotechnology company located in durham, north carolina, united states.